Portfolio Strategy
If I Had ₹50 Lakh to Enter Respiratory, How Would I Build the Portfolio?
A capital-first way to sequence molecules, dosage forms and devices when the budget is finite.
Insights
Respiratory Business Intelligence, Not Product Promotion.
Commercial thinking on portfolio design, device economics, manufacturing partners and institutional access.
Inhalation Devices
DPI vs MDI: The Business Decision Behind the Device
Device choice is a commercial decision before it is a technical one. Here is the trade-off map.
Pharma Entrepreneurship
8 Mistakes Pharma Entrepreneurs Make When Entering Respiratory
The avoidable errors that quietly consume capital in the first eighteen months.
Portfolio Strategy
Why 10 Focused Respiratory Products Can Beat 40 Random SKUs
Focus compounds. Breadth without logic dilutes field time, inventory and positioning.
Commercial Strategy
Third-Party Manufacturing: 12 Questions Before You Sign
A structured screening list for capability, quality systems and commercial economics.
Institutional Sales
From Pulmonologist to Procurement: Understanding Institutional Sales
Why clinical adoption and commercial access have to be designed as one motion.
Respiratory Market Intelligence
Respiratory Portfolio Strategy: Volume vs Value
Where volume plays work, where value plays work, and how to avoid being stuck between them.
Pharma Entrepreneurship
How to Build a Respiratory Business Without Becoming Another Me-Too Company
Differentiation levers that do not require a novel molecule.
Free Download
Free Respiratory Business Opportunity Map 2026
Before investing in a respiratory portfolio, understand where the opportunities—and the risks—are.
- 25 Respiratory Opportunity Categories
- Portfolio Selection Framework
- DPI vs MDI vs Nebulization
- Institutional Opportunity Map
- Third-Party Manufacturing Checklist
- 10 Common Respiratory Launch Mistakes